Avalo Therapeutics (NASDAQ:AVTX) Given New $30.00 Price Target at HC Wainwright

Avalo Therapeutics (NASDAQ:AVTX) had its price objective dropped by HC Wainwright from $35.00 to $30.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 60.43% from the stock’s current price.

A number of other analysts have also commented on the company. Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Weiss Ratings lowered shares of Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research note on Friday, July 24th. BTIG Research restated a “buy” rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Finally, Wolfe Research assumed coverage on shares of Avalo Therapeutics in a report on Thursday, April 9th. They set an “outperform” rating and a $48.00 target price for the company. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Avalo Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $45.30.

Avalo Therapeutics Trading Down 0.7%

AVTX opened at $18.70 on Friday. Avalo Therapeutics has a 1-year low of $8.01 and a 1-year high of $24.27. The stock has a market capitalization of $989.23 million, a PE ratio of -3.42 and a beta of 0.80. The firm has a 50-day moving average price of $17.22 and a two-hundred day moving average price of $16.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). On average, research analysts predict that Avalo Therapeutics will post -2.58 EPS for the current year.

Insider Buying and Selling at Avalo Therapeutics

In other news, insider Mittie Doyle sold 1,450 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the completion of the transaction, the insider owned 51,776 shares of the company’s stock, valued at $931,968. The trade was a 2.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in shares of Avalo Therapeutics by 2.5% in the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after buying an additional 2,648 shares during the period. Glenmede Trust Co. NA raised its holdings in shares of Avalo Therapeutics by 25.8% during the first quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company’s stock worth $384,000 after acquiring an additional 5,280 shares during the period. Dimensional Fund Advisors LP bought a new stake in Avalo Therapeutics in the 3rd quarter valued at $143,000. Boothbay Fund Management LLC bought a new stake in Avalo Therapeutics in the 2nd quarter valued at $56,000. Finally, AlphaCentric Advisors LLC acquired a new position in Avalo Therapeutics in the 1st quarter worth $174,000. 87.06% of the stock is currently owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.